Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.29 (market cap $510.01M), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 250.1× GraniteShares 2x Long COIN Daily ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CONL | VRTX | |
|---|---|---|
Market Cap | $510.01M | $127.55B |
Volume | 21,041,836 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $557.96 |
52-Week Low | $3.93 | $407.37 |
Typical Hold Time | 15 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $5.41, up 3.44% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF, which provides 2x daily leveraged exposure to Coinbase Global stock, faces volatility from its underlying asset's performance. Recent news highlights significant price gaps and volume spikes, with the stock previously gapping up to $6.44 on October 1, 2026.
The outlook remains high-risk due to leveraged structure amplifying Coinbase's volatility. Investment opportunity exists for short-term traders betting on Coinbase rebounds, but risks include rapid decay from daily rebalancing and crypto market downturns. Long-term holders face erosion from volatility drag, requiring careful risk management.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
